Cell-Based Therapies with T Regulatory Cells.

BioDrugs

Department of Clinical Immunology and Transplantology, Medical University of Gdańsk, Dębinki 7, 80-210, Gdańsk, Poland.

Published: August 2017

CD4CD25FoxP3 T regulatory cells (Tregs) are immunodominant suppressors in the immune system. Tregs use various mechanisms to control immune responses. Preclinical data from animal models have confirmed the huge therapeutic potential of Tregs in many immune-mediated diseases. Hence, these cells are now on the road to translation to cell therapy in the clinic as the first clinical trials are accomplished. To date, clinical research has involved mainly hematopoietic stem cell transplantations, solid organ transplantations, and autoimmunity. Despite difficulties with legislation and technical issues, treatment is constantly evolving and may soon represent a valid alternative for patients with diseases that are currently incurable. This review focuses on the basic and clinical experience with Tregs with adoptive transfer of these cells, primarily from clinical trials, as well as on perspectives on clinical use and technical problems with implementing the therapy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5548816PMC
http://dx.doi.org/10.1007/s40259-017-0228-3DOI Listing

Publication Analysis

Top Keywords

regulatory cells
8
clinical trials
8
clinical
5
cell-based therapies
4
therapies regulatory
4
cells
4
cells cd4cd25foxp3
4
cd4cd25foxp3 regulatory
4
tregs
4
cells tregs
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!